Search company, investor...

Predict your next investment

Private Equity

Investments

14

Portfolio Exits

1

About Junson Capital

Junson Capital (佳辰资本) is a private equity real estate investment firm.

Headquarters Location

Hong Kong

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Junson Capital News

Full-Life Technologies Raises USD $47.3M in Series B Funding

Jan 4, 2024

Full-Life Technologies , a Shanghai, China-based radiotherapeutics company, raised USD $63.3M in funding. The round, which included $47.3M in Series B equity financing and $16M in loan facilities, saw participation from Prosperity7 Ventures and an undisclosed healthcare specialist investor, along with new investors Sky9 Capital, Summer Capital, and GuanghuaWutong Fund, as well as existing shareholders Chengwei Capital, HongShan, and Junson Capital. The financing will advance development of the company’s radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. With completion of such financing, Full-Life has secured more than $110M funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies. Full-Life Technologies is a global radiotherapeutics company with operations in Belgium, Germany, and China, which seeks to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. Since completion of its Series A equity financing in 2022, Full-Life has achieved multiple significant milestones, including but not limited to: Advancing the company’s lead drug candidate, 225Ac-FL-020, towards Phase I clinical trials in metastatic castration-resistant prostate cancer (mCRPC) patients. Clinical trials are planned to start in both Europe and the U.S. in early 2024. Full-Life’s PSMA-targeting vector, FL-020, is specifically designed to deliver the highly potent alpha-emitter, Actinium-225. Assembling a pre-clinical portfolio including both first-in-class and best-in-class programs as well as development of the novel UniRDCTM discovery platform. UniRDCTM is a proprietary platform established to streamline the discovery process of RDC. Acquiring a 17,000 square meter of land in the Walloon region of Belgium, obtaining the required construction permit, and beginning construction of a 4,000 square meter state-of-the-art GMP-level radiopharmaceutical production facility. The facility is designed to advance Full-Life’s end-to-end solution and manufacture a broad spectrum of radiopharmaceuticals. FinSMEs 04/01/2024

Junson Capital Investments

14 Investments

Junson Capital has made 14 investments. Their latest investment was in Full-Life as part of their Series B on January 03, 2024.

CBI Logo

Junson Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/3/2024

Series B

Full-Life

$47.3M

No

2

11/30/2023

Series B - II

Allotex

Yes

4

9/20/2023

Series B

Corsair Pharma

$23M

Yes

2

9/14/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/27/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/3/2024

11/30/2023

9/20/2023

9/14/2022

7/27/2022

Round

Series B

Series B - II

Series B

Series B

Series B

Company

Full-Life

Allotex

Corsair Pharma

Subscribe to see more

Subscribe to see more

Amount

$47.3M

$23M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

2

10

10

Junson Capital Portfolio Exits

1 Portfolio Exit

Junson Capital has 1 portfolio exit. Their latest portfolio exit was Apollomics on March 20, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/20/2022

Reverse Merger

$99M

2

Date

3/20/2022

Exit

Reverse Merger

Companies

Valuation

$99M

Acquirer

Sources

2

Junson Capital Team

1 Team Member

Junson Capital has 1 team member, including current Chief Executive Officer, Kevin Liu.

Name

Work History

Title

Status

Kevin Liu

Chief Executive Officer

Current

Name

Kevin Liu

Work History

Title

Chief Executive Officer

Status

Current

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.